Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

BMS-963272Cas# 1441057-15-3

Lipid metabolic flux analysis of compA in intestinal mucosa

The monoacylglycerol acyltransferase pathway contributes to

Frontiers Baicalein Prevents Fructose-Induced Hepatic Steatosis

Efficacy and safety of an orally administered DGAT2 inhibitor

Non-Alcoholic Steatohepatitis disease: Malacards - Research

Targeting diacylglycerol acyltransferase 2 for the treatment of

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Targeted therapeutics and novel signaling pathways in non-alcohol

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Targeting diacylglycerol acyltransferase 2 for the treatment of

Frontiers New insights into the role of dietary triglyceride

Therapeutic Strategies for Metabolic Diseases: Small‐Molecule

Beyond triglyceride synthesis: the dynamic functional roles of